{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:42:49Z","timestamp":1794411769064,"version":"4.9.0"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Dendritic cells (DCs), as the most protent professional antigen-presenting cells (APCs), possess an exceptional capacity to initiate and modulate adaptive immune responses, rendering DC-based vaccines a highly promising approach in tumor immunotherapy. This review explores the biological properties of DCs, establishing a foundation for the rational development of DC vaccine. We further provide a comprehensive overview of current mainstream DC vaccine platforms, with analysis of three representative strategies: (i) DC vaccines loaded with tumor lysates; (ii) personalized neoantigen-pulsed DC vaccines; and (iii) DC-derived exosome vaccines, a rapidly emerging cell-free therapeutic modality. With respect to clinical translation, we summarize the outcomes of clinical trials conducted over the past five years, particularly targeting high-mortality malignancies. While the results are encouraging, the broad clinical application remains limited, posing several challenges, including functional heterogeneity of DCs and immunosuppressive tumor microenvironment, which need to be overcome. Combination strategies, such as DC vaccination paired with chemotherapy, radiotherapy or immune checkpoint blockade, are increasingly recognized as essential for enhancing therapeutic efficacy. With the sustainable progress in tumor immunobiology and advanced bioengineering in the future, the development of DC vaccines will be accelerated, offering novel therapeutic prospects for patients with refractory cancers.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1902454","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:23:56Z","timestamp":1784874236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The promising cancer treatment approach in cancer immunotherapy: dendritic cell-based vaccines"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingwen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xibiao","family":"Jia","sequence":"additional","affiliation":[{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhai","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyao","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"Ca-Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transd Tar"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04241-9","article-title":"Clinical development of cancer vaccines","volume":"32","author":"Haanen","year":"2026","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1038\/s41467-022-32849-1","article-title":"Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cells","volume":"13","author":"Adamik","year":"2022","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117858","article-title":"Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy","volume":"184","author":"Sheykhhasan","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111548","article-title":"The role of dendritic cells in cancer immunity and therapeutic strategies","volume":"128","author":"Tai","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4161\/hv.19795","article-title":"Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer","volume":"8","author":"Gardner","year":"2012","journal-title":"Hum Vacc Immunother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","article-title":"Dendritic cell subsets in T cell programming: location dictates function","volume":"19","author":"Eisenbarth","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.08.014","article-title":"Dendritic cells as shepherds of T cell immunity in cancer","volume":"56","author":"Pittet","year":"2023","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101848","article-title":"Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy","volume":"71","author":"Moussion","year":"2024","journal-title":"Semin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","article-title":"Dendritic cell biology and its role in tumor immunotherapy","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/bs.mie.2020.01.004","article-title":"Monitoring antigen cross-presentation by human dendritic cells purified from peripheral blood","volume":"635","author":"Isnard","year":"2020","journal-title":"Method Enzymol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2467","article-title":"Re(de)fining the dendritic cell lineage","volume":"13","author":"Satpathy","year":"2012","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00628-x","article-title":"Transcriptional divergence between cDC1s and cDC2s: an AP1-IRF composite element-dependent program","volume":"18","author":"Zhu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.cell.2019.09.035","article-title":"Transcriptional basis of mouse and human dendritic cell heterogeneity","volume":"179","author":"Brown","year":"2019","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101729","article-title":"Pathways of MHC I cross-presentation of exogenous antigens","volume":"66","author":"Cruz","year":"2023","journal-title":"Semin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.12688\/f1000research.9997.1","article-title":"The role of cDC1s in vivo: CD8 T cell priming through cross-presentation","volume":"6","author":"Theisen","year":"2017","journal-title":"F1000Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.10.004","article-title":"Type 1 conventional dendritic cells: ontogeny, function, and emerging roles in cancer immunotherapy","volume":"42","author":"Zhang","year":"2021","journal-title":"Trends Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081976","article-title":"The role of type-2 conventional dendritic cells in the regulation of tumor immunity","volume":"14","author":"Saito","year":"2022","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41467-022-35615-5","article-title":"CD4(+) helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment","volume":"14","author":"Lei","year":"2023","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01133-1","article-title":"CD4(+) T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors","volume":"21","author":"Lei","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0074-8","article-title":"Antitumour dendritic cell vaccination in a priming and boosting approach","volume":"19","author":"Harari","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00584","article-title":"Monocyte-derived dendritic cells are essential for CD8(+) T cell activation and antitumor responses after local immunotherapy","volume":"6","author":"Kuhn","year":"2015","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12645-023-00190-x","article-title":"Monocytes reprogrammed by tumor microparticle vaccine inhibit tumorigenesis and tumor development","volume":"14","author":"Sun","year":"2023","journal-title":"Cancer Nanotechnol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","article-title":"The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes","volume":"185","author":"Huang","year":"2022","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13720","article-title":"The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity","volume":"7","author":"Laoui","year":"2016","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1038\/s41598-018-23943-w","article-title":"Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy","volume":"8","author":"Shinde","year":"2018","journal-title":"Sci Rep-Uk"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.immuni.2021.10.009","article-title":"Plasmacytoid dendritic cell activation is dependent on coordinated expression of distinct amino acid transporters","volume":"54","author":"Grzes","year":"2021","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-061020-053707","article-title":"Dendritic cells revisited","volume":"39","author":"Cabeza-Cabrerizo","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","article-title":"Dendritic cells in cancer immunology","volume":"19","author":"Murphy","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00413-x","article-title":"Genetic models of human and mouse dendritic cell development and function","volume":"21","author":"Anderson","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101481","article-title":"The role of dendritic cells in cancer and anti-tumor immunity","volume":"52","author":"Marciscano","year":"2021","journal-title":"Semin Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.immuni.2021.08.012","article-title":"Distinct human Langerhans cell subsets orchestrate reciprocal functions and require different developmental regulation","volume":"54","author":"Liu","year":"2021","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2404927121","article-title":"Monocytes give rise to Langerhans cells that preferentially migrate to lymph nodes at steady state","volume":"121","author":"Raquer-McKay","year":"2024","journal-title":"P Natl Acad Sci USA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/biology12070925","article-title":"MiR-23a regulates skin Langerhans cell phagocytosis and inflammation-induced Langerhans cell repopulation","volume":"12","author":"Wang","year":"2023","journal-title":"Biology-Basel"},{"key":"B42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12967-019-02133-w","article-title":"A phase I\/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma","volume":"17","author":"Sarivalasis","year":"2019","journal-title":"J Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2026.103125","article-title":"Neoantigen-based dendritic cell vaccines in lung cancer: overcoming immunosuppressive barriers for durable antitumor immunity","volume":"145","author":"Li","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082070","article-title":"Dendritic cell-derived exosomes in cancer immunotherapy","volume":"15","author":"Luo","year":"2023","journal-title":"Pharmaceutics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101913","article-title":"Dendritic cell vaccines: Current research progress, challenges, and opportunities","volume":"13","author":"Zhang","year":"2026","journal-title":"Genes Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad088","article-title":"Dendritic cell vaccine trials in gliomas: untangling the lines","volume":"25","author":"Hotchkiss","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300121","article-title":"Rethinking antigen source: Cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell","volume":"10","author":"Diao","year":"2023","journal-title":"Adv Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2025.0267","article-title":"Current progress in neoantigen-based dendritic cell vaccines for solid tumors","volume":"22","author":"Li","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13102497","article-title":"Dendritic cell-derived exosomes: Next generation of cancer immunotherapy","volume":"13","author":"Dhar","year":"2025","journal-title":"Biomedicines"},{"key":"B50","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s12967-024-05457-4","article-title":"Extracellular vesicles at the crossroad between cancer progression and immunotherapy: focus on dendritic cells","volume":"22","author":"Schioppa","year":"2024","journal-title":"J Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121141","article-title":"Engineered porous\/hollow Burkholderia pseudomallei loading tumor lysate as a vaccine","volume":"278","author":"Huang","year":"2021","journal-title":"Biomaterials"},{"key":"B52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"10419","DOI":"10.1038\/s41467-024-54650-y","article-title":"A dendritic cell vaccine for both vaccination and neoantigen-reactive T cell preparation for cancer immunotherapy in mice","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-021-01467-8","article-title":"Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion","volume":"20","author":"Cai","year":"2021","journal-title":"Mol Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003708","article-title":"Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application","volume":"138","author":"Xie","year":"2025","journal-title":"Chin Med J-Peking"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216190","article-title":"Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy","volume":"563","author":"Li","year":"2023","journal-title":"Cancer Lett"},{"key":"B57","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02448-z","article-title":"Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models","volume":"69","author":"Zhang","year":"2020","journal-title":"Cancer Immunol Immun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122481","article-title":"Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma","volume":"306","author":"Pan","year":"2024","journal-title":"Biomaterials"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of Tremelimumab plus Durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105631","article-title":"Remodeling tumor-associated neutrophils to enhance dendritic cell-based HCC neoantigen nano-vaccine efficiency","volume":"9","author":"Wang","year":"2022","journal-title":"Adv Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-024-00305-3","article-title":"Neoantigen-specific mRNA\/DC vaccines for effective anticancer immunotherapy","volume":"25","author":"Zhang","year":"2024","journal-title":"Genes Immun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.11.057","article-title":"Extracellular vesicles and their engineering strategies, delivery systems, and biomedical applications","volume":"365","author":"Yang","year":"2024","journal-title":"J Ctrl Rel"},{"key":"B65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-019-0965-7","article-title":"Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance","volume":"18","author":"Maacha","year":"2019","journal-title":"Mol Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"van Niel","year":"2018","journal-title":"Nat Rev Mol Cell Bio"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202005709","article-title":"Engineered extracellular vesicles for cancer therapy","volume":"33","author":"Zhang","year":"2021","journal-title":"Adv Mater"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00899-0","article-title":"Extracellular vesicles in immunomodulation and tumor progression","volume":"22","author":"Marar","year":"2021","journal-title":"Nat Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.01.001","article-title":"The biology, function, and applications of exosomes in cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B70","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.bioactmat.2022.10.016","article-title":"Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison","volume":"22","author":"Zhang","year":"2023","journal-title":"Bioact Mater"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.03.042","article-title":"Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro","volume":"369","author":"Shamshiripour","year":"2024","journal-title":"J Ctrl Rel"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1465","article-title":"Aberrant chimeric RNA GOLM1-MAK10 encoding a secreted fusion protein as a molecular signature for human esophageal squamous cell carcinoma","volume":"4","author":"Zhang","year":"2013","journal-title":"Oncotarget"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12243","article-title":"Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles","volume":"11","author":"Xiong","year":"2022","journal-title":"J Extracell Vesicles"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113138","article-title":"Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy","volume":"42","author":"Xu","year":"2023","journal-title":"Cell Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101648","article-title":"Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers","volume":"5","author":"Shang","year":"2024","journal-title":"Cell Rep Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12967-026-08111-3","article-title":"Dendritic cell-derived exosomes from PDT-treated glioma cells enhance antitumor immunity as a subcellular vaccine","volume":"24","author":"Wang","year":"2026","journal-title":"J Transl Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0551-7","article-title":"Dendritic cell-tumor cell hybrid vaccination for metastatic cancer","volume":"53","author":"Barbuto","year":"2004","journal-title":"Cancer Immunol Immun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.07.014","article-title":"Phase I\/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma","volume":"125","author":"Kim","year":"2007","journal-title":"Clin Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902841951","article-title":"DCVax-Brain and DC vaccines in the treatment of GBM","volume":"18","author":"Wheeler","year":"2009","journal-title":"Expert Opin Inv Drug"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01509-5","article-title":"A retrospective observational analysis of overall survival with Sipuleucel-T in Medicare beneficiaries treated for advanced prostate cancer","volume":"37","author":"McKay","year":"2020","journal-title":"Adv Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0064","article-title":"A retrospective analysis comparing APCEDEN(\u00ae) dendritic cell immunotherapy with best supportive care in refractory cancer","volume":"9","author":"Kumar","year":"2017","journal-title":"Immunotherapy-Uk"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13697","article-title":"Novel precision medicine approaches and treatment strategies in hematological malignancies","volume":"294","author":"Rosenquist","year":"2023","journal-title":"J Intern Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","article-title":"Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transd Tar"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1496-4","article-title":"DC-based immunotherapy for hematological malignancies","volume":"99","author":"Kitawaki","year":"2014","journal-title":"Int J Hematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01980-3","article-title":"WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy","volume":"37","author":"Floisand","year":"2023","journal-title":"Leukemia"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005941","article-title":"Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant","volume":"6","author":"Chung","year":"2022","journal-title":"Blood Adv"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27349","article-title":"Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients","volume":"99","author":"Tu","year":"2024","journal-title":"Am J Hematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e14515","article-title":"Dendritic cell\u2013based vaccines (KSD-101) against EBV-associated lymphoproliferative diseases: Results from an ongoing phase I clinical study","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-025-02267-0","article-title":"Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies","volume":"24","author":"Pouyan","year":"2025","journal-title":"Mol Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s13046-022-02552-6","article-title":"Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment","volume":"41","author":"Bota","year":"2022","journal-title":"J Exp Clin Canc Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1200\/JCO.2025.43.16_suppl.2014","article-title":"Vaccination by homologous antigenic loading with DOC1021 as adjuvant therapy for glioblastoma: phase I clinical trial results","volume":"43","author":"Georges","year":"2025","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transd Tar"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101516","article-title":"Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum","volume":"5","author":"Ingels","year":"2024","journal-title":"Cell Rep Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009765","article-title":"Dendritic cells pulsed with multifunctional Wilms\u2019 tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer","volume":"12","author":"Koido","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02585","article-title":"Dendritic cell\u2013based immunotherapy in patients with resected pancreatic cancer","volume":"42","author":"Land","year":"2024","journal-title":"J Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103302","article-title":"FDX1 downregulation activates mitophagy and the PI3K\/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production","volume":"75","author":"Sun","year":"2024","journal-title":"Redox Biol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14513","article-title":"A first-in-human study to evaluate a personalized neoantigen-based mRNA-loaded dendritic cell vaccine, in combination with ablation, in patients with hepatocellular carcinoma","volume":"42","author":"Liang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.03.010","article-title":"Blockade of PD-1\/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice","volume":"336","author":"Ge","year":"2013","journal-title":"Cancer Lett"},{"key":"B100","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J Immunother"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.733800","article-title":"Control of dendritic cell function within the tumour microenvironment","volume":"13","author":"Gupta","year":"2022","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00787-3","article-title":"Dendritic cell maturation in cancer","volume":"25","author":"Moon","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.59717\/j.xinn-med.2025.100128","article-title":"Dendritic cells instruct T cell anti-tumor immunity and immunotherapy response","volume":"3","author":"Xiao","year":"2025","journal-title":"Innovation Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.70218","article-title":"Recent advances in natural products for cancer immunotherapy","volume":"40","author":"Liu","year":"2026","journal-title":"Phytother Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: Limitations and effectiveness-a literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.5bt0420-585rr","article-title":"Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside","volume":"108","author":"Roy","year":"2020","journal-title":"J Leukocyte Biol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"23956","DOI":"10.1038\/s41598-024-75376-3","article-title":"A protocol to isolate and characterize pure monocytes and generate monocyte-derived dendritic cells through FBS-coated flasks","volume":"14","author":"Meskini","year":"2024","journal-title":"Sci Rep-Uk"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008219","article-title":"Blocking senescence and tolerogenic function of dendritic cells induced by \u03b3\u03b4 Treg cells enhances tumor-specific immunity for cancer immunotherapy","volume":"12","author":"Si","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1529403","article-title":"Recent advances in novel tumor immunotherapy strategies based on regulating the tumor microenvironment and immune checkpoints","volume":"16","author":"Jing","year":"2025","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1921927","article-title":"Fecal microbiota composition associates with the capacity of human peripheral blood monocytes to differentiate into immunogenic dendritic cells in vitro","volume":"13","author":"Radojevic","year":"2021","journal-title":"Gut Microbes"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573635","article-title":"Dendritic cell-based immunotherapy for head and neck squamous cell carcinoma: Advances and challenges","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00210-y","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","author":"Pearlman","year":"2021","journal-title":"Nat Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1509","article-title":"Characterisation of novel influenza-derived HLA-B*18:01-restricted epitopes","volume":"13","author":"Leong","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2022.02.022","article-title":"Programmed polymersomes with spatio-temporal delivery of antigen and dual-adjuvants for efficient dendritic cells-based cancer immunotherapy","volume":"33","author":"Wang","year":"2022","journal-title":"Chin Chem Lett"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.07.005","article-title":"Dendritic cell vaccines as cancer treatment: Focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal products","volume":"26","author":"Granato","year":"2024","journal-title":"Cytotherapy"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/vaccines8010025","article-title":"Development and optimization of a GMP-compliant manufacturing process for a personalized tumor lysate dendritic cell vaccine","volume":"8","author":"Boudousquie","year":"2020","journal-title":"Vaccines-Basel"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2019.309575","article-title":"Inadequate reporting of analytical characteristics of biomarkers used in clinical research: A threat to interpretation and replication of study findings","volume":"65","author":"Sun","year":"2019","journal-title":"Clin Chem"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized cancer vaccines: Clinical landscape, challenges, and opportunities","volume":"29","author":"Shemesh","year":"2021","journal-title":"Mol Ther"},{"key":"B120","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: A comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003190","article-title":"Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: A phase 2, open-label, multicenter, randomized trial","volume":"10","author":"Rob","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188763","article-title":"The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants","volume":"1877","author":"Ding","year":"2022","journal-title":"Bba-Rev Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.06.003","article-title":"Next-generation cancer vaccines and emerging immunotherapy combinations","volume":"10","author":"Brandenburg","year":"2024","journal-title":"Trends Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41698-022-00279-3","article-title":"Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer","volume":"6","author":"Guo","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02375-z","article-title":"Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: A pooled analysis of two prospective trials","volume":"68","author":"Liang","year":"2019","journal-title":"Cancer Immunol Immun"},{"key":"B127","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12967-017-1165-0","article-title":"Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy","volume":"15","author":"Han","year":"2017","journal-title":"J Transl Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s12916-023-03132-x","article-title":"A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas","volume":"21","author":"Zhou","year":"2023","journal-title":"BMC Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1200\/JCO.2024.42.16_suppl.2545","article-title":"Updated results on multiple antigens stimulating cellular therapy (MASCT-I) in metastatic urothelial carcinoma: A randomized, open-label, phase I trial","volume":"42","author":"Shi","year":"2024","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658670","article-title":"Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): Protocol for a randomized controlled trial","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01798","article-title":"Synergistic antimyeloma activity of dendritic cells and pomalidomide in a murine myeloma model","volume":"9","author":"Vo","year":"2018","journal-title":"Front Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01370","article-title":"Lenalidomide and programmed death-1 blockade synergistically enhances the effects of dendritic cell vaccination in a model of murine myeloma","volume":"9","author":"Vo","year":"2018","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111363","article-title":"The advantages and challenges of anticancer dendritic cell vaccines and NK cells in adoptive cell immunotherapy","volume":"9","author":"Abakushina","year":"2021","journal-title":"Vaccines-Basel"},{"key":"B134","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: From basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56685","article-title":"Late-stage ovarian cancer with systemic multiple metastases shows marked shrinkage using a combination of Wilms' tumor antigen 1 (WT1) dendritic cell vaccine, natural killer (NK) cell therapy, and nivolumab","volume":"16","author":"Nagai","year":"2024","journal-title":"Cureus"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101413","article-title":"Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma","volume":"20","author":"Chu","year":"2022","journal-title":"Transl Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.4103\/hm.HM-D-25-00046","article-title":"Challenges in cardio-oncology and psycho-oncology","volume":"9","author":"Liu","year":"2025","journal-title":"Heart Mind"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1902454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:23:57Z","timestamp":1784874237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1902454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":138,"alternative-id":["10.3389\/fimmu.2026.1902454"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1902454","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1902454"}}